ROME Therapeutics Presents First Data to Validate LINE-1 RT as a Novel Target in Autoimmune Diseases and the Therapeutic Potential of its First-in-Class LINE-1 RT Inhibitors

Presentation at the American College of Rheumatology Convergence 2023 showcased first-ever data correlating LINE-1 expression and type 1 interferon response in skin of patients with lupus ROME's first-in-class LINE-1 reverse [...]